Lumexa Imaging (NASDAQ:LMRI) received an upgrade from Raymond James Financial, moving from an “outperform” rating to a “strong-buy” rating. This announcement was made in a research note issued to investors on Monday, indicating a positive outlook for the company’s stock.
The brokerage has set a price target of $23.00 for Lumexa Imaging, suggesting a potential upside of 112.96% from the stock’s current trading price. Following the upgrade, Lumexa Imaging’s shares rose by 6.5%, opening at $10.80.
Recent Trading and Institutional Investments
Lumexa Imaging has experienced notable fluctuations over the past year, with a twelve-month low of $9.97 and a high of $19.45. These dynamics reflect the company’s growth potential within the diagnostic imaging sector.
In addition to the upgrade, there has been recent institutional interest in Lumexa Imaging. Assetmark Inc. disclosed that it acquired a new position in the company during the fourth quarter, purchasing 1,957 shares valued at approximately $36,000. This investment underscores confidence among institutional investors in Lumexa Imaging’s future prospects.
About Lumexa Imaging
Lumexa Imaging is recognized as one of the largest national providers of diagnostic imaging services in the United States. The company operates an integrated and scalable platform that has demonstrated its ability to create value for stakeholders. As of September 30, 2025, Lumexa Imaging and its affiliates manage the second largest outpatient imaging center footprint in the country, comprising 184 centers spread across 13 states. This network includes eight joint venture partnerships with various health systems, strategically located in attractive metropolitan statistical areas.
The upgrade from Raymond James Financial, coupled with increased institutional investment, signals a growing confidence in Lumexa Imaging’s operational model and market position. Investors will be closely monitoring the company’s performance as it navigates a competitive landscape in the diagnostic imaging sector.
